FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL											
	OMB Number:	3235-0287										
ı	Estimated average b	ourden										

0.5

hours per response:

	Check this box if no longer subject to
)	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_		. ,				nparty Act	01 10-			· · ·			5 (): 1		
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Ciaffoni Joseph</u>						[COLL]							-	X Director		tor	10% (Owner		
(Last)	(E	iret) (Middle)												X	Office	er (give title v)	Other below	(specify	
(Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC.						3. Date of Earliest Transaction (Month/Day/Year)									President and CEO					
100 TECHNOLOGY CENTER DRIVE					02/	02/08/2019														
					- 4. If	If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)															Line)					
STOUGH	HTON M	A 02072													X	Form filed by One Reporting Person Form filed by More than One Reporting				
					1											Pers		e tilali Olle Kej	Jording	
(City)	(S	tate) (Zip)																	
		Tabl	le I - Noi	n-Deriv	ative	Sec	curitie	s Acc	quired,	Dis	posed o	f, oı	r Ben	efici	ally C)wne	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution ay/Year) if any		cution Date,		Transaction Disposed Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3, 4			1 and Secu Bene Own		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	. 17	Reported Transaction(s) (Instr. 3 and 4)			(111501.4)	
Common Stock 02/08/2					/2019				F 2,05		2,052(1	2 ⁽¹⁾ D \$		\$14	.39	196,606		D		
		Та									sed of, onvertib				y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis. Expiration Date (Month/Day/Yea		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		estr. 3	8. Prio Deriva Secur (Instr.	vative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nui of	ount mber ares						

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Remarks:

/s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni 02/11/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.